Research profile
Bremelanotide/PT-141
Bremelanotide, also called PT-141, activates melanocortin receptors. An approved U.S. prescription formulation is indicated for acquired, generalized hypoactive sexual desire disorder in premenopausal women.
- Phase 3 clinical trials
- Evaluation only
Amnavero
Bremelanotide/PT-141
What the research found
Two phase 3 trials evaluated patient-reported sexual desire and distress. Both measures improved with bremelanotide relative to placebo.
What remains uncertain
The evidence covers the population studied. The prescribing information includes cardiovascular restrictions and describes common adverse reactions such as nausea.